PCSK9 and coronary artery disorder: For example, the efficacy of lipid-lowering drug targets in reducing risk of coronary artery disease has been shown by previous MR studies, for therapies such as statins (which target HMG-CoA reductase (HMGCR)), proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and Ezetimibe (which targets Niemann–Pick C1-Like 1 (NPC1L1)) [20,21].